Gene
NPM1
NPM1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (37), Actionable biomarkers (2), Trial mentions (165), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NPM1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 29 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 26 of 8,738 | 0.30% | not measured | |
| 2025 | 19 of 8,875 | 0.21% | not measured | |
| 2024 | 22 of 8,597 | 0.26% | not measured | |
| 2023 | 9 of 8,275 | 0.11% | 40 of 11,460 | 0.35% |
| 2022 | 9 of 8,285 | 0.11% | 44 of 13,598 | 0.32% |
| 2021 | 13 of 8,692 | 0.15% | 41 of 15,045 | 0.27% |
| 2020 | 4 of 7,640 | 0.05% | 41 of 14,459 | 0.28% |
| 2019 | 11 of 7,300 | 0.15% | 35 of 12,159 | 0.29% |
| 2018 | 6 of 6,927 | 0.09% | 29 of 11,854 | 0.24% |
| 2017 | 4 of 6,558 | 0.06% | 31 of 11,595 | 0.27% |
Showing 10 of 37 years.
Assay-provider ledger (37)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Pittsburgh Medical Center | Not a company | Clinical validation | 1 | June 04, 2026 |
| Sengenics | Reagent supplier | Clinical validation | 1 | May 05, 2026 |
| BD BioSciences | Reagent supplier | Analytical validation | 1 | May 08, 2025 |
| Life Technologies | Reagent supplier | Clinical validationAnalytical validation | 2 | May 08, 2025 |
| Promega | Reagent supplier | Analytical validation | 1 | May 08, 2025 |
Showing 5 of 37 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NPM1 oncogenic mutation | Dot1l Inhibitors + Mll1 Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| NPM1 oncogenic mutation | Daunorubicin | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
Trial mentions (165)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04925609 | Trial eligibility (AACT) |
| NCT04588922 | Trial eligibility (AACT) |
| NCT01465386 | Trial eligibility (AACT) |
| NCT02722668 | Trial eligibility (AACT) |
| NCT03739502 | Trial eligibility (AACT) |
Showing 5 of 165 trial mentions.
Target-disease associations (488)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Anal fistula | phenotype | Mouse knockout (IMPC) |
Showing 5 of 488 associations.
Vendor sourcing (556)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AVEO Oncology (United States) | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | (EC): * Acute promyelocytic leukemia (APL) * Clinically active CNS involvement by AML. A patient may be considered eligible if CNS leukemia is showing respo... | View trial NCT03013998 |
| AVEO Oncology (United States) | Trial collaborator | Primary endpoint in a Phase 3 trialTrial endpoint | BAML-16-001-S26/HO177: Overall survival (OS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy. | View trial NCT03013998 |
| AVEO Oncology (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | NPM1 | View trial NCT03013998 |
| AbbVie Inc. | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Diagnosis of Acute promyelocytic leukemia (APL) or AML with favorable cytogenetics \[t(8;21), inv(16), t(16;16)\] * Patients \< 60 years old with NPM1-m... | View trial NCT04801797 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. A signed informed consent 2. Newly diagnosed CD33-positive AML with NPM1 mutation according to WHO criteria 3. Age 18-70 years 4. Fit for intensive che... | View trial NCT05904106 |
Showing 5 of 556 sourcing records.
Trial-cited literature (472)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. | Blood | 2026 | 5 |
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 201 |
| Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. | Blood | 2025 | 60 |
| Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 46 |
Showing 5 of 472 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.R123H | 1 | 2010 | PMID 20376086 |
| p.T95D | 1 | 2005 | PMID 16041368 |
Literature-extracted relations (101)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML. | 2025 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. | 2023 |
| Gemtuzumab | Chemical | negative_correlate |
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. | 2023 |
| Lomustine | Chemical | associate |
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. | 2021 |
| Daunorubicin | Chemical | negative_correlate |
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. | 2016 |
Showing 5 of 101 relation assertions.
Organizations publishing (476)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 40 | 2011 to 2026 |
| Dana-Farber Cancer Institute | Other | 37 | 2009 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 28 | 2012 to 2025 |
| Mayo Clinic | Hospital | 20 | 2016 to 2025 |
| Medizinische Hochschule Hannover | Academic | 19 | 2011 to 2026 |
Showing 5 of 476 organizations.
Where NPM1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- respiratory or thoracic disease
- urinary system disease
441 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.